Evotec SE (EVO) Stock Competitors & Peer Comparison
See (EVO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EVO | $2.68 | -4.80% | 976.8M | -4.37 | -$0.63 | N/A |
| TAK | $15.79 | +0.32% | 49.7B | 41.36 | $0.38 | +3.93% |
| HLN | $9.17 | +3.04% | 40.5B | 18.24 | $0.50 | +2.12% |
| TEVA | $33.94 | +2.04% | 40.1B | 25.70 | $1.34 | N/A |
| VTRS | $15.94 | +0.03% | 18.9B | -54.00 | -$0.30 | +2.93% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.73 | +0.21% | 12.2B | -48.98 | -$0.50 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.44 | +1.59% | 11.1B | 25.23 | $0.53 | +0.68% |
| RGC | $20.57 | -3.86% | 10B | -2031.00 | -$0.01 | N/A |
Stock Comparison
EVO vs TAK Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, TAK has a market cap of 49.7B. Regarding current trading prices, EVO is priced at $2.68, while TAK trades at $15.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas TAK's P/E ratio is 41.36. In terms of profitability, EVO's ROE is -0.24%, compared to TAK's ROE of +0.03%. Regarding short-term risk, EVO is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check TAK's competition here
EVO vs HLN Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, HLN has a market cap of 40.5B. Regarding current trading prices, EVO is priced at $2.68, while HLN trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas HLN's P/E ratio is 18.24. In terms of profitability, EVO's ROE is -0.24%, compared to HLN's ROE of +0.17%. Regarding short-term risk, EVO is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check HLN's competition here
EVO vs TEVA Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, TEVA has a market cap of 40.1B. Regarding current trading prices, EVO is priced at $2.68, while TEVA trades at $33.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas TEVA's P/E ratio is 25.70. In terms of profitability, EVO's ROE is -0.24%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, EVO is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TEVA's competition here
EVO vs VTRS Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, VTRS has a market cap of 18.9B. Regarding current trading prices, EVO is priced at $2.68, while VTRS trades at $15.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas VTRS's P/E ratio is -54.00. In terms of profitability, EVO's ROE is -0.24%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, EVO is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check VTRS's competition here
EVO vs ITCI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, EVO is priced at $2.68, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ITCI's P/E ratio is -180.64. In terms of profitability, EVO's ROE is -0.24%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, EVO is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check ITCI's competition here
EVO vs ELAN Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ELAN has a market cap of 12.2B. Regarding current trading prices, EVO is priced at $2.68, while ELAN trades at $23.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ELAN's P/E ratio is -48.98. In terms of profitability, EVO's ROE is -0.24%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, EVO is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ELAN's competition here
EVO vs CTLT Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, EVO is priced at $2.68, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas CTLT's P/E ratio is -27.84. In terms of profitability, EVO's ROE is -0.24%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, EVO is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check CTLT's competition here
EVO vs RDY Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, RDY has a market cap of 11.1B. Regarding current trading prices, EVO is priced at $2.68, while RDY trades at $13.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas RDY's P/E ratio is 25.23. In terms of profitability, EVO's ROE is -0.24%, compared to RDY's ROE of +0.12%. Regarding short-term risk, EVO is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check RDY's competition here
EVO vs RGC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, RGC has a market cap of 10B. Regarding current trading prices, EVO is priced at $2.68, while RGC trades at $20.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas RGC's P/E ratio is -2031.00. In terms of profitability, EVO's ROE is -0.24%, compared to RGC's ROE of -2.32%. Regarding short-term risk, EVO is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check RGC's competition here
EVO vs LNTH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, EVO is priced at $2.68, while LNTH trades at $101.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas LNTH's P/E ratio is 23.86. In terms of profitability, EVO's ROE is -0.24%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, EVO is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check LNTH's competition here
EVO vs INDV Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, EVO is priced at $2.68, while INDV trades at $38.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas INDV's P/E ratio is 19.62. In terms of profitability, EVO's ROE is -0.24%, compared to INDV's ROE of -1.42%. Regarding short-term risk, EVO is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check INDV's competition here
EVO vs AMRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, AMRX has a market cap of 4.7B. Regarding current trading prices, EVO is priced at $2.68, while AMRX trades at $15.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas AMRX's P/E ratio is 39.70. In terms of profitability, EVO's ROE is -0.24%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, EVO is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check AMRX's competition here
EVO vs SUPN Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, EVO is priced at $2.68, while SUPN trades at $45.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas SUPN's P/E ratio is -89.53. In terms of profitability, EVO's ROE is -0.24%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, EVO is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SUPN's competition here
EVO vs DCPH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, EVO is priced at $2.68, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas DCPH's P/E ratio is -11.58. In terms of profitability, EVO's ROE is -0.24%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, EVO is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check DCPH's competition here
EVO vs AVDL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, EVO is priced at $2.68, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, EVO's ROE is -0.24%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, EVO is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check AVDL's competition here
EVO vs BHC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, BHC has a market cap of 1.9B. Regarding current trading prices, EVO is priced at $2.68, while BHC trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas BHC's P/E ratio is -1.60. In terms of profitability, EVO's ROE is -0.24%, compared to BHC's ROE of +1.21%. Regarding short-term risk, EVO is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check BHC's competition here
EVO vs EMBCV Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, EVO is priced at $2.68, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas EMBCV's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.24%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, EVO is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check EMBCV's competition here
EVO vs HCM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, HCM has a market cap of 1.9B. Regarding current trading prices, EVO is priced at $2.68, while HCM trades at $10.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas HCM's P/E ratio is 4.01. In terms of profitability, EVO's ROE is -0.24%, compared to HCM's ROE of +0.41%. Regarding short-term risk, EVO is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check HCM's competition here
EVO vs ANIP Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, EVO is priced at $2.68, while ANIP trades at $83.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ANIP's P/E ratio is 20.77. In terms of profitability, EVO's ROE is -0.24%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, EVO is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ANIP's competition here
EVO vs DVAX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, EVO is priced at $2.68, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas DVAX's P/E ratio is -41.89. In terms of profitability, EVO's ROE is -0.24%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, EVO is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check DVAX's competition here
EVO vs TARO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, EVO is priced at $2.68, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas TARO's P/E ratio is 30.05. In terms of profitability, EVO's ROE is -0.24%, compared to TARO's ROE of +0.03%. Regarding short-term risk, EVO is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check TARO's competition here
EVO vs PRGO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, PRGO has a market cap of 1.5B. Regarding current trading prices, EVO is priced at $2.68, while PRGO trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas PRGO's P/E ratio is -0.86. In terms of profitability, EVO's ROE is -0.24%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, EVO is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check PRGO's competition here
EVO vs ALVOW Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ALVOW has a market cap of 1.4B. Regarding current trading prices, EVO is priced at $2.68, while ALVOW trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ALVOW's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.24%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, EVO is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ALVOW's competition here
EVO vs PAHC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, EVO is priced at $2.68, while PAHC trades at $32.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas PAHC's P/E ratio is 14.01. In terms of profitability, EVO's ROE is -0.24%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, EVO is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check PAHC's competition here
EVO vs ALVO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, EVO is priced at $2.68, while ALVO trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ALVO's P/E ratio is 41.60. In terms of profitability, EVO's ROE is -0.24%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, EVO is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ALVO's competition here
EVO vs HROW Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, EVO is priced at $2.68, while HROW trades at $35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas HROW's P/E ratio is -88.05. In terms of profitability, EVO's ROE is -0.24%, compared to HROW's ROE of -0.34%. Regarding short-term risk, EVO is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check HROW's competition here
EVO vs COLL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, COLL has a market cap of 1.1B. Regarding current trading prices, EVO is priced at $2.68, while COLL trades at $35.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas COLL's P/E ratio is 16.70. In terms of profitability, EVO's ROE is -0.24%, compared to COLL's ROE of +0.27%. Regarding short-term risk, EVO is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check COLL's competition here
EVO vs CRON Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, CRON has a market cap of 1B. Regarding current trading prices, EVO is priced at $2.68, while CRON trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas CRON's P/E ratio is -139.50. In terms of profitability, EVO's ROE is -0.24%, compared to CRON's ROE of -0.00%. Regarding short-term risk, EVO is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check CRON's competition here
EVO vs PETQ Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, EVO is priced at $2.68, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas PETQ's P/E ratio is 83.73. In terms of profitability, EVO's ROE is -0.24%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, EVO is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check PETQ's competition here
EVO vs PCRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, PCRX has a market cap of 913M. Regarding current trading prices, EVO is priced at $2.68, while PCRX trades at $23.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas PCRX's P/E ratio is 178.54. In terms of profitability, EVO's ROE is -0.24%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, EVO is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check PCRX's competition here
EVO vs AMPH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, AMPH has a market cap of 888.9M. Regarding current trading prices, EVO is priced at $2.68, while AMPH trades at $20.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas AMPH's P/E ratio is 12.14. In terms of profitability, EVO's ROE is -0.24%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, EVO is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check AMPH's competition here
EVO vs TLRY Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, TLRY has a market cap of 618.4M. Regarding current trading prices, EVO is priced at $2.68, while TLRY trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas TLRY's P/E ratio is -0.35. In terms of profitability, EVO's ROE is -0.24%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, EVO is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TLRY's competition here
EVO vs BDSI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, EVO is priced at $2.68, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas BDSI's P/E ratio is 6.82. In terms of profitability, EVO's ROE is -0.24%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, EVO is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check BDSI's competition here
EVO vs IRWD Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, IRWD has a market cap of 530.1M. Regarding current trading prices, EVO is priced at $2.68, while IRWD trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas IRWD's P/E ratio is 5.19. In terms of profitability, EVO's ROE is -0.24%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, EVO is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check IRWD's competition here
EVO vs EOLS Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, EOLS has a market cap of 441.2M. Regarding current trading prices, EVO is priced at $2.68, while EOLS trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas EOLS's P/E ratio is -10.15. In terms of profitability, EVO's ROE is -0.24%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, EVO is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check EOLS's competition here
EVO vs CGC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, CGC has a market cap of 434.4M. Regarding current trading prices, EVO is priced at $2.68, while CGC trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas CGC's P/E ratio is -0.76. In terms of profitability, EVO's ROE is -0.24%, compared to CGC's ROE of -0.51%. Regarding short-term risk, EVO is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check CGC's competition here
EVO vs KMDA Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, KMDA has a market cap of 417.6M. Regarding current trading prices, EVO is priced at $2.68, while KMDA trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas KMDA's P/E ratio is 20.69. In terms of profitability, EVO's ROE is -0.24%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, EVO is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check KMDA's competition here
EVO vs AQST Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, AQST has a market cap of 396.2M. Regarding current trading prices, EVO is priced at $2.68, while AQST trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas AQST's P/E ratio is -6.54. In terms of profitability, EVO's ROE is -0.24%, compared to AQST's ROE of +1.91%. Regarding short-term risk, EVO is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check AQST's competition here
EVO vs SNDL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, SNDL has a market cap of 379.8M. Regarding current trading prices, EVO is priced at $2.68, while SNDL trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas SNDL's P/E ratio is -48.67. In terms of profitability, EVO's ROE is -0.24%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, EVO is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check SNDL's competition here
EVO vs ORGO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ORGO has a market cap of 319.1M. Regarding current trading prices, EVO is priced at $2.68, while ORGO trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ORGO's P/E ratio is -20.67. In terms of profitability, EVO's ROE is -0.24%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, EVO is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ORGO's competition here
EVO vs SIGA Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, SIGA has a market cap of 314.9M. Regarding current trading prices, EVO is priced at $2.68, while SIGA trades at $4.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas SIGA's P/E ratio is 15.68. In terms of profitability, EVO's ROE is -0.24%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, EVO is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SIGA's competition here
EVO vs ALIM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, EVO is priced at $2.68, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ALIM's P/E ratio is 5.28. In terms of profitability, EVO's ROE is -0.24%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, EVO is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check ALIM's competition here
EVO vs LNDC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, EVO is priced at $2.68, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas LNDC's P/E ratio is -4.04. In terms of profitability, EVO's ROE is -0.24%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, EVO is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check LNDC's competition here
EVO vs TKNO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, TKNO has a market cap of 239.1M. Regarding current trading prices, EVO is priced at $2.68, while TKNO trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas TKNO's P/E ratio is -13.94. In terms of profitability, EVO's ROE is -0.24%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, EVO is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TKNO's competition here
EVO vs TYHT Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, EVO is priced at $2.68, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas TYHT's P/E ratio is -1.61. In terms of profitability, EVO's ROE is -0.24%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, EVO is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TYHT's competition here
EVO vs LFCR Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, LFCR has a market cap of 212.3M. Regarding current trading prices, EVO is priced at $2.68, while LFCR trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas LFCR's P/E ratio is -4.46. In terms of profitability, EVO's ROE is -0.24%, compared to LFCR's ROE of -1.76%. Regarding short-term risk, EVO is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check LFCR's competition here
EVO vs ACB Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ACB has a market cap of 199.8M. Regarding current trading prices, EVO is priced at $2.68, while ACB trades at $3.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ACB's P/E ratio is -3.16. In terms of profitability, EVO's ROE is -0.24%, compared to ACB's ROE of -0.08%. Regarding short-term risk, EVO is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ACB's competition here
EVO vs EMBC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, EMBC has a market cap of 196.4M. Regarding current trading prices, EVO is priced at $2.68, while EMBC trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas EMBC's P/E ratio is 1.75. In terms of profitability, EVO's ROE is -0.24%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, EVO is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check EMBC's competition here
EVO vs REPH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, EVO is priced at $2.68, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas REPH's P/E ratio is -8.04. In terms of profitability, EVO's ROE is -0.24%, compared to REPH's ROE of -0.22%. Regarding short-term risk, EVO is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check REPH's competition here
EVO vs DERM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, DERM has a market cap of 170.1M. Regarding current trading prices, EVO is priced at $2.68, while DERM trades at $6.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas DERM's P/E ratio is -16.70. In terms of profitability, EVO's ROE is -0.24%, compared to DERM's ROE of -0.36%. Regarding short-term risk, EVO is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check DERM's competition here
EVO vs THTX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, EVO is priced at $2.68, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas THTX's P/E ratio is -17.84. In terms of profitability, EVO's ROE is -0.24%, compared to THTX's ROE of +0.17%. Regarding short-term risk, EVO is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check THTX's competition here
EVO vs OGI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, OGI has a market cap of 152M. Regarding current trading prices, EVO is priced at $2.68, while OGI trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas OGI's P/E ratio is -7.20. In terms of profitability, EVO's ROE is -0.24%, compared to OGI's ROE of -0.07%. Regarding short-term risk, EVO is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check OGI's competition here
EVO vs ASRT Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ASRT has a market cap of 151.6M. Regarding current trading prices, EVO is priced at $2.68, while ASRT trades at $23.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ASRT's P/E ratio is -4.23. In terms of profitability, EVO's ROE is -0.24%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, EVO is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check ASRT's competition here
EVO vs CRDL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, CRDL has a market cap of 120.8M. Regarding current trading prices, EVO is priced at $2.68, while CRDL trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas CRDL's P/E ratio is -3.86. In terms of profitability, EVO's ROE is -0.24%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, EVO is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check CRDL's competition here
EVO vs SCTL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, EVO is priced at $2.68, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas SCTL's P/E ratio is -7.86. In terms of profitability, EVO's ROE is -0.24%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, EVO is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check SCTL's competition here
EVO vs PROC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, EVO is priced at $2.68, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas PROC's P/E ratio is 1.53. In terms of profitability, EVO's ROE is -0.24%, compared to PROC's ROE of -2.22%. Regarding short-term risk, EVO is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check PROC's competition here
EVO vs OPTN Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, EVO is priced at $2.68, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas OPTN's P/E ratio is -4.42. In terms of profitability, EVO's ROE is -0.24%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, EVO is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check OPTN's competition here
EVO vs ZOM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, EVO is priced at $2.68, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ZOM's P/E ratio is -1.62. In terms of profitability, EVO's ROE is -0.24%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, EVO is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ZOM's competition here
EVO vs GRVI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, EVO is priced at $2.68, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas GRVI's P/E ratio is 26.05. In terms of profitability, EVO's ROE is -0.24%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, EVO is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check GRVI's competition here
EVO vs CPIX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, CPIX has a market cap of 85.7M. Regarding current trading prices, EVO is priced at $2.68, while CPIX trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas CPIX's P/E ratio is -11.67. In terms of profitability, EVO's ROE is -0.24%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, EVO is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check CPIX's competition here
EVO vs ZYNE Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, EVO is priced at $2.68, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, EVO's ROE is -0.24%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, EVO is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ZYNE's competition here
EVO vs BGM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, BGM has a market cap of 69.3M. Regarding current trading prices, EVO is priced at $2.68, while BGM trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas BGM's P/E ratio is -1.19. In terms of profitability, EVO's ROE is -0.24%, compared to BGM's ROE of -0.03%. Regarding short-term risk, EVO is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check BGM's competition here
EVO vs SSIC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, EVO is priced at $2.68, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas SSIC's P/E ratio is 11.93. In terms of profitability, EVO's ROE is -0.24%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, EVO is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SSIC's competition here
EVO vs VLNS Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, EVO is priced at $2.68, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas VLNS's P/E ratio is -1.03. In terms of profitability, EVO's ROE is -0.24%, compared to VLNS's ROE of N/A. Regarding short-term risk, EVO is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check VLNS's competition here
EVO vs DRRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, EVO is priced at $2.68, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas DRRX's P/E ratio is -4.44. In terms of profitability, EVO's ROE is -0.24%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, EVO is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check DRRX's competition here
EVO vs INCR Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, INCR has a market cap of 52.7M. Regarding current trading prices, EVO is priced at $2.68, while INCR trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas INCR's P/E ratio is -4.19. In terms of profitability, EVO's ROE is -0.24%, compared to INCR's ROE of -0.09%. Regarding short-term risk, EVO is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check INCR's competition here
EVO vs JUPW Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, EVO is priced at $2.68, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas JUPW's P/E ratio is -2.41. In terms of profitability, EVO's ROE is -0.24%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, EVO is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check JUPW's competition here
EVO vs ZYBT Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ZYBT has a market cap of 42.2M. Regarding current trading prices, EVO is priced at $2.68, while ZYBT trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ZYBT's P/E ratio is -4.05. In terms of profitability, EVO's ROE is -0.24%, compared to ZYBT's ROE of -0.26%. Regarding short-term risk, EVO is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ZYBT's competition here
EVO vs IXHL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, IXHL has a market cap of 42.1M. Regarding current trading prices, EVO is priced at $2.68, while IXHL trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas IXHL's P/E ratio is -0.22. In terms of profitability, EVO's ROE is -0.24%, compared to IXHL's ROE of -1.23%. Regarding short-term risk, EVO is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check IXHL's competition here
EVO vs QLI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, EVO is priced at $2.68, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas QLI's P/E ratio is -4.92. In terms of profitability, EVO's ROE is -0.24%, compared to QLI's ROE of -0.16%. Regarding short-term risk, EVO is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check QLI's competition here
EVO vs HEXO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, EVO is priced at $2.68, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas HEXO's P/E ratio is -0.26. In terms of profitability, EVO's ROE is -0.24%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, EVO is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check HEXO's competition here
EVO vs SCYX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, SCYX has a market cap of 27.4M. Regarding current trading prices, EVO is priced at $2.68, while SCYX trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas SCYX's P/E ratio is -1.14. In terms of profitability, EVO's ROE is -0.24%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, EVO is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SCYX's competition here
EVO vs RMTI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, RMTI has a market cap of 27.1M. Regarding current trading prices, EVO is priced at $2.68, while RMTI trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas RMTI's P/E ratio is -4.57. In terms of profitability, EVO's ROE is -0.24%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, EVO is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check RMTI's competition here
EVO vs CYTH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, EVO is priced at $2.68, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas CYTH's P/E ratio is -0.80. In terms of profitability, EVO's ROE is -0.24%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, EVO is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check CYTH's competition here
EVO vs TXMD Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, TXMD has a market cap of 21.8M. Regarding current trading prices, EVO is priced at $2.68, while TXMD trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas TXMD's P/E ratio is 188.00. In terms of profitability, EVO's ROE is -0.24%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, EVO is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check TXMD's competition here
EVO vs EVOK Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, EVO is priced at $2.68, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas EVOK's P/E ratio is -7.97. In terms of profitability, EVO's ROE is -0.24%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, EVO is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check EVOK's competition here
EVO vs AYTU Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, AYTU has a market cap of 18.6M. Regarding current trading prices, EVO is priced at $2.68, while AYTU trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas AYTU's P/E ratio is -0.49. In terms of profitability, EVO's ROE is -0.24%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, EVO is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check AYTU's competition here
EVO vs QNTM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, QNTM has a market cap of 17.5M. Regarding current trading prices, EVO is priced at $2.68, while QNTM trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas QNTM's P/E ratio is -0.50. In terms of profitability, EVO's ROE is -0.24%, compared to QNTM's ROE of -6.22%. Regarding short-term risk, EVO is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check QNTM's competition here
EVO vs TLPH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, TLPH has a market cap of 16.7M. Regarding current trading prices, EVO is priced at $2.68, while TLPH trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas TLPH's P/E ratio is -2.91. In terms of profitability, EVO's ROE is -0.24%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, EVO is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TLPH's competition here
EVO vs OPTH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, OPTH has a market cap of 15.7M. Regarding current trading prices, EVO is priced at $2.68, while OPTH trades at $4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas OPTH's P/E ratio is -3.95. In terms of profitability, EVO's ROE is -0.24%, compared to OPTH's ROE of -0.57%. Regarding short-term risk, EVO is less volatile compared to OPTH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check OPTH's competition here
EVO vs ACRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, EVO is priced at $2.68, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ACRX's P/E ratio is -0.31. In terms of profitability, EVO's ROE is -0.24%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, EVO is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ACRX's competition here
EVO vs COSM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, COSM has a market cap of 13.4M. Regarding current trading prices, EVO is priced at $2.68, while COSM trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas COSM's P/E ratio is -0.34. In terms of profitability, EVO's ROE is -0.24%, compared to COSM's ROE of -0.96%. Regarding short-term risk, EVO is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check COSM's competition here
EVO vs BFRI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, BFRI has a market cap of 10.8M. Regarding current trading prices, EVO is priced at $2.68, while BFRI trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas BFRI's P/E ratio is -0.86. In terms of profitability, EVO's ROE is -0.24%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, EVO is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check BFRI's competition here
EVO vs AGRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, EVO is priced at $2.68, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas AGRX's P/E ratio is -0.89. In terms of profitability, EVO's ROE is -0.24%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, EVO is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check AGRX's competition here
EVO vs NLTX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, EVO is priced at $2.68, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas NLTX's P/E ratio is -0.28. In terms of profitability, EVO's ROE is -0.24%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, EVO is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check NLTX's competition here
EVO vs EGRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, EGRX has a market cap of 7.9M. Regarding current trading prices, EVO is priced at $2.68, while EGRX trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas EGRX's P/E ratio is 8.57. In terms of profitability, EVO's ROE is -0.24%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, EVO is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check EGRX's competition here
EVO vs LCI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, EVO is priced at $2.68, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas LCI's P/E ratio is -0.04. In terms of profitability, EVO's ROE is -0.24%, compared to LCI's ROE of +1.66%. Regarding short-term risk, EVO is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check LCI's competition here
EVO vs YCBD Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, YCBD has a market cap of 7.4M. Regarding current trading prices, EVO is priced at $2.68, while YCBD trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas YCBD's P/E ratio is 0.28. In terms of profitability, EVO's ROE is -0.24%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, EVO is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check YCBD's competition here
EVO vs BGXX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, EVO is priced at $2.68, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas BGXX's P/E ratio is -0.76. In terms of profitability, EVO's ROE is -0.24%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, EVO is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check BGXX's competition here
EVO vs ADMP Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, EVO is priced at $2.68, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ADMP's P/E ratio is -0.08. In terms of profitability, EVO's ROE is -0.24%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, EVO is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ADMP's competition here
EVO vs MNK Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, EVO is priced at $2.68, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas MNK's P/E ratio is -0.44. In terms of profitability, EVO's ROE is -0.24%, compared to MNK's ROE of -0.26%. Regarding short-term risk, EVO is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check MNK's competition here
EVO vs GELS Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, GELS has a market cap of 4.5M. Regarding current trading prices, EVO is priced at $2.68, while GELS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas GELS's P/E ratio is -0.96. In terms of profitability, EVO's ROE is -0.24%, compared to GELS's ROE of -0.43%. Regarding short-term risk, EVO is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check GELS's competition here
EVO vs FLGC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, EVO is priced at $2.68, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas FLGC's P/E ratio is -0.19. In terms of profitability, EVO's ROE is -0.24%, compared to FLGC's ROE of -0.08%. Regarding short-term risk, EVO is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check FLGC's competition here
EVO vs GHSI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, EVO is priced at $2.68, while GHSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas GHSI's P/E ratio is -0.79. In terms of profitability, EVO's ROE is -0.24%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, EVO is more volatile compared to GHSI. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check GHSI's competition here
EVO vs PLXP Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, EVO is priced at $2.68, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas PLXP's P/E ratio is -0.22. In terms of profitability, EVO's ROE is -0.24%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, EVO is less volatile compared to PLXP. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check PLXP's competition here
EVO vs RDHL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, RDHL has a market cap of 2.5M. Regarding current trading prices, EVO is priced at $2.68, while RDHL trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas RDHL's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.24%, compared to RDHL's ROE of +2.91%. Regarding short-term risk, EVO is less volatile compared to RDHL. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check RDHL's competition here
EVO vs ATNX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, EVO is priced at $2.68, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas ATNX's P/E ratio is -0.02. In terms of profitability, EVO's ROE is -0.24%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, EVO is more volatile compared to ATNX. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check ATNX's competition here
EVO vs CPHI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, CPHI has a market cap of 2.3M. Regarding current trading prices, EVO is priced at $2.68, while CPHI trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas CPHI's P/E ratio is -1.33. In terms of profitability, EVO's ROE is -0.24%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, EVO is less volatile compared to CPHI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check CPHI's competition here
EVO vs UPC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 976.8M. In comparison, UPC has a market cap of 2M. Regarding current trading prices, EVO is priced at $2.68, while UPC trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -4.37, whereas UPC's P/E ratio is -0.44. In terms of profitability, EVO's ROE is -0.24%, compared to UPC's ROE of -0.07%. Regarding short-term risk, EVO is less volatile compared to UPC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check UPC's competition here